COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies. 

By Kelly Bilodeau • June 2, 2025

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

By Amy Baxter • June 2, 2025

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

What’s next for Trump’s ‘most favored nation’ policy?

HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.

By Amy Baxter • May 27, 2025

The placebo effect: How a new FDA rule could pile more strain onto vaccine developers

The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.

By Alexandra Pecci • May 20, 2025

With the third round of Medicare price negotiations on the way, here’s how the policy is shifting

HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.  

By Amy Baxter • May 19, 2025

Tracking a moving target: Drugmakers brace for a looming tariff impact

With policies in flux, companies seek to be proactive and understand their supply chain.

By Kelly Bilodeau • May 19, 2025

Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.

The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.

By Amy Baxter • May 14, 2025

FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

By Alexandra Pecci • May 13, 2025

RFK Jr.’s autism fixation hearkens back to his stance on vaccines

The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

By Amy Baxter • May 9, 2025

Prasad’s FDA appointment pressures cell and gene therapy stocks

A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

By Ben Fidler • May 7, 2025

With TV ads under threat, here’s how pharma can leverage social media

RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

By Amy Baxter • May 7, 2025

On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

By Michael Gibney • May 6, 2025

Is pharma ready to let go of animal testing?

Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

By Meagan Parrish • May 2, 2025

J&J scores FDA OK for immune drug touted as future blockbuster

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

By Ned Pagliarulo • May 1, 2025

Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

By Michael Gibney • May 1, 2025

Is the FDA headed for a major reorganization?

A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture. 

By Amy Baxter • April 30, 2025

US backlash against mRNA vaccines could hinder scientific progress

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

By Michael Gibney • April 29, 2025

FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

By Amy Baxter • April 28, 2025

What’s being cut at NIH

A look at the government’s far-reaching rollback in research grants so far.

By Meagan Parrish • April 25, 2025

Trump reveals pharma reform priorities in drug pricing executive order

The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.  

By Amy Baxter • April 23, 2025

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

HHS layoffs may be illegal, legal experts say

The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.

By Rebecca Pifer • April 17, 2025

Novartis scores NFL deal to tackle health outcomes

The non-traditional marketing approach comes amid a potential crackdown on TV drug ads. 

By Amy Baxter • April 17, 2025

The fallout from UnitedHealth’s CEO slaying

Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.

By PharmaVoice staff • April 15, 2025